⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DWTX News
Dogwood Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
DWTX
Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.
globenewswire.com
DWTX
Dogwood to Participate in the 2026 Maxim Growth Summit
globenewswire.com
DWTX
Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
globenewswire.com
DWTX
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
globenewswire.com
DWTX
Form 8-K
sec.gov
DWTX
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
globenewswire.com
DWTX
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
globenewswire.com
DWTX
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
globenewswire.com
DWTX
Form 8-K
sec.gov
DWTX